✓ checked
trust me, bro:
here is the receipt.
the claim
Immunotherapeutics are used in the treatment of metastatic renal cell carcinoma.
the verdict
SUPPORTED
the evidence backs this
Recorded sources
8 sources for · 0 against
Is it true that Immunotherapeutics are used in the treatment of metastatic renal cell carcinoma?
Yes. Immunotherapeutics, particularly immune checkpoint inhibitors like nivolumab and pembrolizumab, are widely established as standard first-line and subsequent treatments for metastatic renal cell carcinoma.
Verdict: SUPPORTED · 8 sources for, 0 against · Last checked
The analysis
The retrieved papers extensively discuss the use of immune checkpoint inhibitors (such as nivolumab, ipilimumab, and pembrolizumab) either as monotherapy or in combination regimens (such as with tyrosine kinase inhibitors) for treating metastatic renal cell carcinoma. The evidence consistently supports the claim.
Evidence for · 8
Evaluates biomarker efficacy in metastatic clear-cell renal cell carcinoma patients treated with nivolumab or ipilimumab-nivolumab.
Get citation
Lu, X., Vano, Y., Su, X., Verkarre, V., Sun, C., Cheng, W., Xu, L., Yan, F., Kotti, S., Fridman, W. H., Sautes-Fridman, C., Oudard, S., & Malouf, G. (2025). Stratification system with dual human endogenous retroviruses for predicting immunotherapy efficacy in metastatic clear-cell renal cell carcinoma. doi.org. https://doi.org/10.1136/jitc-2024-010386
See more details
More for · 7
Examines the effectiveness of nivolumab-based immunotherapy in older patients with metastatic renal cell carcinoma.
Get citation
Murianni, V., Campione, M., Cremante, M., Basso, U., Fratino, L., Buti, S., Bracarda, S., Maruzzo, M., Giorgi, U. d., Tortora, G., Chiellino, S., Antonuzzo, L., Galli, L., Zucali, P., Rizzo, M., Signori, A., Giannarelli, D., Procopio, G., Rescigno, P., Fornarini, G., Rebuzzi, S. E., & Banna, G. (2025). Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinoma.. doi.org. https://doi.org/10.1016/j.jgo.2025.102336
Analyzes outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor combinations.
Get citation
Yekedüz, E., Zarba, M., Saad, E., Chehade, R. E. H., Eid, M., Saliby, R., Steiner, C., Machaalani, M., Nawfal, R., Semaan, K., Ürün, Y., Heng, D. Y. C., & Choueiri, T. (2025). Comorbidity Burden and Effectiveness of Immunotherapy in Metastatic Renal Cell Carcinoma.. doi.org. https://doi.org/10.1016/j.clgc.2025.102385
Investigates clinical predictors of treatment failure in metastatic renal cell carcinoma patients receiving immune checkpoint inhibitors.
Get citation
Săftescu, S., Vornicu, V., Popovici, D., Dragomir, R., Nagy, D., Sandu, D., Dulan, A., Negru, Ș., & Negru, A. (2025). Decoding Treatment Failures in Metastatic Renal Cell Carcinoma: Predictors Across Immunotherapy and Targeted Therapies from a Retrospective Real-World Analysis. doi.org. https://doi.org/10.3390/jcm14155271
Performs a meta-analysis on immunotherapy rechallenge and immune checkpoint inhibitor combinations in metastatic renal cell carcinoma.
Get citation
Bolek, H., Yazgan, S. C., Yekedüz, E., McGregor, B., McKay, R., Pal, S., Choueiri, T., & Ürün, Y. (2025). Immunotherapy rechallenge in metastatic renal cell carcinoma: a meta-analysis of randomized clinical trials. doi.org. https://doi.org/10.1093/oncolo/oyaf426
Compares clinical outcomes of trial-eligible and ineligible patients with metastatic renal cell carcinoma receiving front-line immunotherapy regimens.
Get citation
Reynolds, N., Wei, W., Maroli, K., Bonham, A., Nizam, A., Gilligan, T., Wee, C., Gupta, S., & Ornstein, M. (2024). Clinical Outcomes for Metastatic Renal Cell Carcinoma (mRCC) Patients Ineligible for Front-line Clinical Trials. doi.org. https://doi.org/10.15586/jkcvhl.v11i3.352
Discusses immunotherapy-based combination therapies as standard care for metastatic renal cell carcinoma in a clinical trial protocol.
Get citation
Troisi, P., Ciccarese, C., Arduini, D., Neri, A., Minervini, A., Ficarra, V., Simone, G., Calabrò, F., Franzese, C., Francolini, G., Morganti, A., Tagliaferri, L., Jereczek-Fossa, B., Porta, C., Zucali, P., Gambacorta, M., Sighinolfi, C., Rocco, B., Tortora, G., & Iacovelli, R. (2026). The ITALIC-RCC study: A randomized study of clinical and humoral impact of primary tumor ablation in metastatic renal cell carcinoma treated with immunotherapy.. doi.org. https://doi.org/10.1200/jco.2026.44.7_suppl.tps584
Demonstrates that first-line anti-PD-1 immunotherapy combinations significantly improve survival over sunitinib in advanced renal cell carcinoma.
Get citation
Kridis, W. B. & Khanfir, A. (2025). First-Line Anti-PD-1 Immunotherapy with Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: A Meta-Analysis by PD-1 Subtype.. doi.org. https://doi.org/10.1097/UPJ.0000000000000963
What does the evidence say?
The retrieved papers extensively discuss the use of immune checkpoint inhibitors (such as nivolumab, ipilimumab, and pembrolizumab) either as monotherapy or in combination regimens (such as with tyrosine kinase inhibitors) for treating metastatic renal cell carcinoma. The evidence consistently supports the claim.
Receipt History
Anyone with this link can read the claim and its public receipt, including any
personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check
or guarantee a response time.
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work
Terms · Privacy · How verdicts work